| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary "target" of Hemoglobin S is not a receptor or enzyme in the traditional sense, but rather the molecular pathology involves the hemoglobin protein itself and its interactions. In sickle cell disease, the abnormal Hemoglobin S polymerizes upon deoxygenation, forming long fibers that distort red blood cells into sickle shapes. This polymerization is the central pathogenic event in SCD. Therapeutic strategies targeting Hemoglobin S aim to either prevent its polymerization (e.g., by increasing fetal hemoglobin levels or using anti-sickling agents) or to manage the downstream consequences of sickling. Hemoglobin S can also be used as a research tool to measure fetal hemoglobin by time-resolved immunofluorescence assay. In this context, the "target" is the hemoglobin molecule itself, and assays are designed to quantify its levels or to detect its presence in biological samples.
|
|---|---|
| ln Vitro |
In vitro activity of Hemoglobin S is primarily studied in the context of its polymerization behavior and its interactions with other hemoglobin variants. The compound's key property is its tendency to polymerize under low oxygen tension, which can be quantified in vitro using assays that measure the kinetics and extent of polymerization. Hemoglobin S can be used in time-resolved immunofluorescence assays to measure fetal hemoglobin levels. In research settings, Hemoglobin S is often employed as a reference standard or control in assays designed to detect or quantify hemoglobin variants. It does not exhibit pharmacological activity in the sense of enzyme inhibition or receptor modulation; rather, its relevance lies in its biophysical properties and its role as the pathogenic protein in sickle cell disease.
|
| ln Vivo |
In vivo activity of Hemoglobin S is manifested in the pathophysiology of sickle cell disease, where the abnormal hemoglobin leads to hemolytic anemia, vaso-occlusive crises, and multi-organ damage. The polymerization of deoxygenated Hemoglobin S within red blood cells causes these cells to become rigid and sickle-shaped, leading to increased blood viscosity, impaired microcirculation, and tissue ischemia. In research contexts, Hemoglobin S is not administered as a therapeutic agent but is studied in animal models of sickle cell disease (e.g., transgenic mice expressing human Hemoglobin S) to understand disease mechanisms and to test potential therapies. The in vivo "activity" of Hemoglobin S is thus its pathogenic role in SCD, which is the focus of extensive research aimed at developing treatments that prevent polymerization or mitigate its consequences.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assay protocols are not directly applicable to Hemoglobin S, as it is not an enzyme or a receptor ligand. However, Hemoglobin S is used in biochemical assays to study its properties and interactions. A typical protocol for studying Hemoglobin S polymerization involves preparing a solution of deoxygenated Hemoglobin S (e.g., by adding sodium dithionite or by equilibrating with nitrogen gas) and monitoring turbidity or light scattering over time as polymers form. The kinetics of polymerization can be assessed by measuring the delay time before the onset of polymerization and the rate of polymer formation. For immunoassay applications, time-resolved immunofluorescence assays use antibodies specific to fetal hemoglobin or other hemoglobin variants to quantify Hemoglobin S levels in blood samples. These assays typically involve capture antibodies immobilized on solid phases, detection with europium-labeled antibodies, and time-resolved fluorescence measurement.
|
| Cell Assay |
In vitro cell-based assay protocols for Hemoglobin S typically use erythroid cell lines or primary erythroid cells to study the effects of Hemoglobin S on cellular function. A common approach involves culturing erythroid progenitor cells (e.g., from sickle cell disease patients or from transgenic mouse models) and inducing erythroid differentiation to produce red blood cells expressing Hemoglobin S. The sickling of these cells can be induced by deoxygenation (e.g., by adding sodium metabisulfite or by incubating under hypoxic conditions), and the percentage of sickled cells can be quantified by microscopy. Cell-based assays may also assess the effects of potential anti-sickling agents on Hemoglobin S polymerization and cell morphology. Other endpoints include assessment of red blood cell deformability using ektacytometry, hemolysis measurements, and evaluation of adhesion properties of sickle erythrocytes to endothelial cells.
|
| Animal Protocol |
In vivo animal experimental protocols involving Hemoglobin S typically use transgenic mouse models of sickle cell disease that express human Hemoglobin S. These models (e.g., Berkeley SCD mice, Townes SCD mice) develop many of the hematological and pathological features of human SCD, including hemolytic anemia, vaso-occlusion, and organ damage. A typical protocol involves breeding and maintaining these transgenic mice, administering test compounds (potential anti-sickling agents) by oral gavage, intraperitoneal injection, or other routes, and monitoring disease-related endpoints. Endpoints include hematological parameters (hemoglobin, hematocrit, reticulocyte count, white blood cell count), assessment of sickling in blood smears, measurement of hemolysis markers (e.g., plasma hemoglobin, bilirubin), evaluation of organ pathology (spleen, liver, kidney, lung), and survival analysis. The mice are used to evaluate the efficacy of potential therapeutics for sickle cell disease.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Hemoglobin S as a protein target rather than a drug compound. Hemoglobin S is the abnormal hemoglobin variant found in red blood cells of individuals with sickle cell disease. It is not administered as a therapeutic agent; rather, it is the pathogenic protein that is the target of therapeutic intervention. In the context of research, Hemoglobin S is used as a reference material for assay development and as a model protein for studying sickle cell disease pathophysiology. Its concentration in red blood cells is determined by the β-globin gene genotype (e.g., homozygous HbSS, heterozygous HbAS). The half-life of red blood cells containing Hemoglobin S is significantly shortened (10-20 days compared to 120 days for normal red blood cells) due to hemolysis, which is a key feature of sickle cell disease.
|
| Toxicity/Toxicokinetics |
Toxicological properties are not applicable to Hemoglobin S as a therapeutic agent, as it is the pathogenic protein in sickle cell disease rather than a drug. The toxicity of Hemoglobin S is manifested in the clinical manifestations of sickle cell disease, including hemolytic anemia, vaso-occlusive crises, acute chest syndrome, stroke, and multi-organ failure. These pathological effects result from the polymerization of deoxygenated Hemoglobin S, leading to red blood cell sickling, increased blood viscosity, microvascular occlusion, and tissue ischemia-reperfusion injury. In research settings, Hemoglobin S is handled as a potentially hazardous biological material, and appropriate biosafety precautions should be followed. The compound is not intended for human use as a therapeutic agent and is supplied for research purposes only.
|
| References | |
| Additional Infomation |
Hemoglobin S is the abnormal hemoglobin variant responsible for sickle cell disease (SCD), a genetic blood disorder affecting millions worldwide. The condition is caused by a point mutation in the HBB gene encoding the β-globin chain, resulting in the substitution of valine for glutamic acid at position 6. Hemoglobin S polymerizes upon deoxygenation, causing red blood cells to assume a sickle shape, leading to hemolytic anemia, vaso-occlusive crises, and chronic organ damage. Hemoglobin S is used in research applications to study the pathophysiology of SCD and to develop and evaluate potential therapeutic interventions. It can be utilized to measure fetal hemoglobin through time-resolved immunofluorescence assays. No therapeutic products containing Hemoglobin S have been approved for clinical use. However, therapies targeting Hemoglobin S polymerization or its downstream effects (e.g., hydroxyurea, voxelotor, crizanlizumab, L-glutamine) have been approved for SCD treatment. Hemoglobin S itself remains a research tool and reference standard.
|
| CAS # |
9035-22-7
|
|---|---|
| Appearance |
Orange to red solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
